Related Experiment Video
Updated: Jun 1, 2026
11:10
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
[Hypoglycemia hypersinsulinemic of infancy]
Raphael Del Roio Liberatore Junior1, Carlos Eduardo Martinelli Junior
1Serviço de Endocrinologia Pediátrica, Departamento de Pediatria e Cirurgia Pediátrica, Faculdade de Medicina de São José do Rio Preto, SP, Brasil. liberat@famerp.br
Arquivos Brasileiros De Endocrinologia E Metabologia
|June 10, 2011
Summary
Infantile hyperinsulinism (HHI) is a neonatal emergency where the brain lacks energy. This review covers HHI diagnosis across infancy and adolescence, including molecular basis and mutations.
Area of Science:
- Pediatric Endocrinology
- Neonatology
- Molecular Genetics
Context:
- Infantile hyperinsulinism (HHI) presents as a critical neonatal emergency.
- Profound hypoglycemia occurs due to excessive insulin secretion, depriving the brain of glucose.
- Timely diagnosis and management are crucial to prevent neurological damage.
Purpose:
- To provide a comprehensive overview of hyperinsulinemic hypoglycemia (HH) diagnosis.
- To extend the diagnostic scope beyond the neonatal period into late infancy and adolescence.
- To detail the molecular alterations and genetic mutations underlying HH.
Summary:
- This review examines the diagnosis of hyperinsulinemic hypoglycemia (HH) across different age groups, from neonates to adolescents.
- It explores the molecular mechanisms and specific genetic mutations responsible for HH.
- The importance of early diagnosis and understanding genetic underpinnings is highlighted.
Impact:
- Enhances understanding of HH diagnostic criteria across developmental stages.
- Facilitates earlier and more accurate diagnosis of HH in infants and adolescents.
- Contributes to the knowledge base for genetic counseling and targeted therapies for HH.
Related Concept Videos
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
01:19Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...